馬飛，1976年生，籍貫江蘇鹽城，腫瘤內科學家，中國醫學科學院腫瘤醫院主任醫師，博士生導師，教育部國家級重大人才項目入選者。1994年考入中國協和醫科大學（現北京協和醫學院）臨床醫學（八年制）專業，2002年獲得臨床醫學博士學位。2002年進入中國醫學科學院腫瘤醫院工作，從事實體腫瘤藥物治療的臨床與研究工作，2016年任主任醫師。

長期致力于乳腺癌等實體瘤的基礎、臨床及轉化研究。在腫瘤創新藥物臨床與轉化研究、腫瘤轉移與耐藥機制研究、液體活檢與精準診療研究、腫瘤大數據研究等領域開展了系列工作。

爆草黑丝美女|韩国19禁无遮挡啪啪无码网站|91精品国产自产精品男人的天堂|sm鞭打高潮喷水抽搐调教玩弄|果冻在线|日本大尺度吃奶呻吟视频|久久久久黄片|北条麻妃av免费观看|中文字幕一区二区人妻|亚洲最大天堂无码精品区,日韩 欧美 国产精品,国产肉丝袜在线观看,最爽无遮挡行房视频,成人H视频在线观看,糖心vlog冉冉,蜜桃产品一二三产区

1. Yuanyuan Zhang#, Hongyan Chen#, Hongnan Mo#, Xueda Hu#, Ranran Gao, Yahui Zhao, Baolin Liu, Lijuan Niu, Xiaoying Sun, Xiao Yu, Yong Wang, Qing Chang, Tongyang Gong, Xiuwen Guan, Ting Hu, Tianyi Qian, Binghe Xu*, Fei Ma*, Zemin Zhang*, Zhihua Liu*. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021, 39(12):1578-1593 (IF=38.585)

2. Zongbi Yi#, Fei Ma*, Guohua Rong, Binliang Liu, Yanfang Guan, Jin Li, Xiaoying Sun, Wenna Wang, Xiuwen Guan, Hongnan Mo, Jiani Wang, Haili Qian, Binghe Xu*. The molecular tumor burden index as a response evaluation criterion in breast cancer. Signal Transduct Target Ther. 2021, 6(1):251. (IF=38.104)

3. Binghe Xu#*, Min Yan#, Fei Ma#, Xichun Hu, Jifeng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Yuanting Gu, Qianjun Chen, Jinping Liu, Jing Cheng, Cuizhi Geng, Shukui Qin, Shusen Wang, Jinsong Lu, Kunwei Shen, Qiang Liu, Xiaojia Wang, Hong Wang, Ting Luo, Jin Yang, Yudong Wu, Zhiyong Yu, Xiaoyu Zhu, Chunxia Chen, Jianjun Zou, PHOEBE Investigators. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021, 22(3):351-360. (IF=54.433)

4. Hui Li#, Jinsong Wang, Zongbi Yi, Chunxiao Li, Haijuan Wang, Jingyao Zhang, Ting Wang, Peng Nan, Feng Lin, Dongkui Xu, Haili Qian*, Fei Ma*. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT. Eur J Cancer. 2021, 145:92-108. (IF=10.002).

5. Hui-Yao Huang#, Da-Wei Wu#, Fei Ma#, Zhi-Lei Liu, Ju-Fang Shi, Xia Chen, Shu-Hang Wang, Hong Fang, Ying Bai, Yue Yu, Yuan Fang, Chao Sun, Qi Fan, Ying Wu, Rui-Hua Fan, Cai-Yun Zhou, Bao-Xia He, Min Dai, Ning Li*, Bing-He Xu, Yan Sun, Jie He. Availability of anticancer biosimilars in 40 countries. Lancet Oncol. 2020, 21(2):197-201. (IF=41.316)

6. Jian Liu #, Chunxiao Li #, Jinsong Wang #, Dongkui Xu#, Haijuan Wang, Ting Wang, Lina Li, Hui Li, Peng Nan, Jingyao Zhang, Yang Wang, Changzhi Huang, Dong Chen, Yi Zhang, Tao Wen*, Qimin Zhan*, Fei Ma*, Haili Qian*. Chromatin modifier MTA1 regulates mitotic transition and tumorigenesis by orchestrating mitotic mRNA processing. Nat Commun. 2020 Sep 8;11(1):4455. (IF=14.919).

7. Fei Ma#*, Yanfang Guan#, Zongbi Yi#, Lianpeng Chang#, Qiao Li, Shanshan Chen, Wenjie Zhu, Xiuwen Guan, Chunxiao Li, Haili Qian, Xuefeng Xia, Ling Yang, Jianjun Zhang, Hatim Husain, Zhongxing Liao, Andrew Futreal, Jian Huang, Xin Yi*, Binghe Xu*. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Int J Cancer. 2020, 146(5):1359-1368. (IF=7.316)

8. Fei Ma#, Quchang Ouyang#, Wei Li, Zefei Jiang, Zhongsheng Tong, Yunjiang Liu, Huiping Li, Shiying Yu, Jifeng Feng, Shusen Wang, Xichun Hu, Jianjun Zou, Xiaoyu Zhu, Binghe Xu*. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. J Clin Oncol. 2019, 37(29):2610-2619. (IF=32.956)

9. Qiao Li#, Xiuwen Guan#, Shanshan Chen, Zongbi Yi, Bo Lan, Puyuan Xing, Ying Fan, Jiayu Wang, Yang Luo, Peng Yuan, Ruigang Cai, Pin Zhang, Qing Li, Dafang Zhong, Yifan Zhang, Jianjun Zou, Xiaoyu Zhu, Fei Ma*, Binghe Xu*. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. Clin Cancer Res. 2019, 25(17):5212-5220. (IF=10.107)

10. Fei Ma#, Qiao Li#, Shanshan Chen, Wenjie Zhu, Ying Fan, Jiayu Wang, Yang Luo, Puyuan Xing, Bo Lan, Meiying Li, Zongbi Yi, Ruigang Cai, Peng Yuan, Pin Zhang, Qing Li, Binghe Xu*. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. 2017, J Clin Oncol. 35(27):3105-3112. (IF=26.303).